ArticleFrontiers in medicine2025
Lung function of tuberculosis patients after completion of treatment in Sidama, South Ethiopia.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Systemic Gaps and Roadmap for Integrated Care for Post-tuberculosis Lung Disease in Ethiopia: A Narrative Review.Cureus · 2026Review
- Article
- Lung Function Assessment Among Patients Previously Treated for Pulmonary Tuberculosis at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.Ethiopian journal of health sciences · 2025Article
- TAK1 phosphorylation mediates macozinone (PBTZ169) induced innate immune activation against tuberculosis.mSphere · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lung function impairment are commonly reported after treatment of pulmonary tuberculosis (TB). This study aimed to examine lung function parameters among adults who have undergone treatment for pulmonary TB. Methods: A comparative cross-sectional study was conducted in eight rural communities of Dale district of Sidama Region, Southern Ethiopia. The post-TB group were smear-positive TB patients who successfully completed TB treatment between 2010 and 2021, while controls were selected from the neighbors of these participants with no documented history of TB. Lung function tests were conducted using a portable spirometer, and pulmonary symptoms were assessed using the Saint Georges Respiratory Questionnaire. Obstructive pulmonary impairment was defined as the ratio of FEV1/FVC below 70% and restrictive impairment was defined as having a normal FEV1/FVC ratio with a low FEV Results: We enrolled 167 TB cases and 156 controls in the study. The median (IQR) was 38 (21) years for cases and 35 (21.75) years for controls. The median (IQR) time after completion of TB treatment was 24 (31.75) months for the TB cases. A higher proportion of post-TB participants (101/167 (60.5%; 95% confidence interval (CI), 52.9-67.6%)) than controls (63/156 (40.4%; 95% CI, 33.0-48.2%)) had obstructive impairment, Conclusion: Post-TB participants had greater risk of pulmonary impairment and respiratory symptoms. Post-TB treatment follow-up care is suggested to quickly identify and manage pulmonary impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.